Therapeutic promise of α-hederin in Alzheimer’s disease: Insights into inflammation, oxidative stress, and apoptosis modulation

This review examines the therapeutic potential of α-Hederin, a triterpenoid saponin sourced from Hedera helix and Nigella sativa, in relation to Alzheimer's disease (AD). Alzheimer's disease is a multifactorial neurodegenerative condition marked by amyloid-β accumulation, tau hyperphosphorylation, oxidative stress, neuroinflammation, synaptic impairment, and neuronal degeneration. Current medications are predominantly symptomatic and do not impede disease progression, highlighting the pressing necessity for multi-targeted medicines. α-Hederin has exhibited potential neuroprotective properties in preclinical investigations, facilitated by the inhibition of amyloid-β aggregation, regulation of tau kinases, suppression of NF-κB-mediated inflammation, augmentation of antioxidant defenses through Nrf2 activation, and modulation of PI3K/Akt survival pathways. Moreover, α-Hederin enhances cholinergic neurotransmission, diminishes apoptosis, and bolsters cognitive performance in animal models. This study comprehensively delineates the molecular targets and signaling pathways modulated by α-Hederin, contrasts its efficacy with other natural and synthetic therapeutic agents, and identifies deficiencies in translational research. Particular attention is directed on issues like as inadequate bioavailability and restricted pharmacokinetic information, in conjunction with novel approaches like nanocarrier-based delivery to improve its effectiveness. This study integrates contemporary molecular and preclinical discoveries, positioning α-Hederin as a multifunctional, disease-modifying option for prospective Alzheimer's therapy.